Yuhan corporation | Radio Compass News

Yuhan makes $325M cancer bet to challenge Boehringer, Takeda

31 May 2023 //

FIERCE BIOTECH

Hanmi, LG Chem, Yuhan race to develop new obesity drug

23 May 2022 //

KOREABIOMED

Yuhan gets $9.97M milestone payment from Boehringer Ingelheim for NASH therapy

17 Nov 2021 //

KOREABIOMED

Yuhan gets $65m from Janssen for lazertinib milestone achievement

23 Nov 2020 //

KOREAHERALD

Yuhan in-licenses GI Innovation’s allergy treatment pipeline for $1.2b

01 Jul 2020 //

KOREAHERALD

After inking a string of pipeline deals, Boehringer Ingelheim is doing makeover

26 Aug 2019 //

ENDPTS

Boehringer Ingelheim Gambles $2.62 Billion on Two Fibrotic Disease Deals

19 Jul 2019 //

BIOSPACE

Boehringer Ingelheim and Yuhan Corp. in US$870m NASH deal

02 Jul 2019 //

EUROPEAN BIOTECHNOLOGY

Pfizer plant closures; Gilead-Yuhan NASH pact; Fujifilm expansions

11 Jan 2019 //

FIERCE PHARMA

Glenmark in second licensing deal for anti-histamine

10 Jan 2019 //

PRESS RELEASE

Gilead adds another shot on the NASH goal with $785M Yuhan pact

09 Jan 2019 //

FIERCE BIOTECH

Yuhan, Gilead sign deal to develop new liver drug

07 Jan 2019 //

KOREA HERALD

Gilead stuffs another NASH drug discovery program into a growing portfolio

04 Jan 2019 //

ENDPTS

Yuhan Corporation collaborates with Syntekabio for AI platform

10 Apr 2018 //

BIOSPECTRUM

Top Korean pharma companies increase their R&D spending in H1

16 Aug 2017 //